Page 6 - Pharma Sector

IPC, Jharkhand Pharmacy Council sign MoU to boost pharmacovigilance, safety

The Indian Pharmacopoeia Commission (IPC), Ghaziabad, on Saturday inked an MoU with the Jharkhand State Pharmacy Council (JSPC) to promote safe and rational medicine use and strengthen pharmacovigilance in Jharkhand. The Indian Pharmacopoeia Commission (IPC), Ghaziabad, is an autonomous institution under the Union Health Ministry. Through this collaboration, IPC and JSPC will work together to build the capacity of registered pharmacists in areas related to adverse drug reaction (ADR) reporting, pharmacovigilance and materiovigilance practices, and the safe use of medicines, a health ministry statement said. The partnership envisions strengthening the utilisation of the National Formulary of India (NFI) as a standard reference document across healthcare facilities in Jharkhand and promoting its systematic use by pharmacists to support rational dispensing and safe medication practices. It further includes coordinated efforts to organise awareness programmes for hospital and community

Akums Q2 PAT falls 35.8% on muted CDMO biz growth, declining API prices

Despite this, the CDMO segment remained Akums' key growth driver, contributing Rs 804 crore, or 79 per cent of its total revenue

Lupin share rises 2% as arm commissions Oncology block at Vizag facility

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.

Nomura lifts Lupin target price on US momentum, India growth recovery

However, on the bourses, Lupin shares were trading 0.70 per cent lower at ₹1,973.50 per share at 9:30 AM. In comparison, BSE Sensex was trading 0.23 per cent lower at 83,346.45 levels.

Apollo Hospitals expects restructuring to conclude by Q4FY27: CFO

Apollo Hospitals CFO says the restructuring and listing of its digital and pharmacy businesses will be completed by the last quarter of FY27, after approvals from regulators including SEBI and NCLT.

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook

Zydus Life Q2 results review: Foreign brokerage Nomura said Zydus Life delivered results above estimates, led by a stronger-than-expected performance in India.

Innovative portfolio likely to maintain growth momentum for Sun Pharma

Specialty portfolio powers Q2; Ilumya, Leqselvi, Unloxcyt to anchor next phase

Sun Pharma Q2 preview: Profit may dip YoY despite revenue growth; details

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

Cipla Q2 results: Profit rises 4%, revenue hits record ₹7,589 crore

The company bets on Eli Lilly tie-up for GLP-1 drug, biosimilars expansion; reaffirms $1 billion US revenue goal

India's pharma, healthcare deals surge 166% to $3.5 bn in Q3: Report

Grant Thornton Bharat says India's pharma and healthcare sectors saw renewed investor confidence, driven by consolidation across pharma, biotech, and hospital segments

Pharma, healthcare sector deals hit $3.5 billion in Sep quarter: Report

Indian pharmaceutical and healthcare sector recorded a total of 72 transactions valued at USD 3.5 billion in the third quarter ended September this year, according to Grant Thornton Bharat's dealtracker. This included three IPOs worth USD 428 million and one QIP worth USD 88 million, Grant Thornton Bharat said in a statement. Excluding public market activity, private deals accounted for USD 3 billion across 68 transactions, marking a sharp rebound in investor appetite, it added. The surge was driven by seven high value deals worth USD 2.6 billion, reflecting renewed investor confidence in scale and consolidation plays across pharma, biotech, and hospital segments, and mirroring the sector's strong fundamentals and growth potential. The standout transaction of the quarter was Torrent Pharma's USD 1.4 billion acquisition of a 46 per cent stake in JB Chemicals & Pharmaceuticals, strengthening its position in high-growth therapeutic segments and chronic care markets, it added. "Q3 ...

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Nuvama retains 'Hold' on Cipla, raises target after Eli Lilly diabetes deal

Cipla- Eli Lilly deal: Tirzepatide is a prescription drug used for managing type 2 diabetes and aiding weight loss in adults who are obese or overweight.

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

Results preview: Pharma sales may be up 9-10% in Q2 on robust domestic biz

Domestic business and exports are expected to be a shot in the arm; hospitals and diagnostics to lag

Graph AI raises $3 mn from Bessemer to target $8 bn drug safety market

California-based Graph AI raised $3 million in seed funding led by Bessemer Venture Partners to scale its AI-driven pharmacovigilance platform for global drug safety and compliance

Cough syrup deaths: SC rejects PIL seeking CBI probe, safety review

The Supreme Court on Friday dismissed a PIL seeking an inquiry and systemic reform in drug safety mechanisms in the wake of deaths of children in Madhya Pradesh and Rajasthan allegedly due to consumption of toxic cough syrups. A bench comprising Chief Justice B R Gavai and Justices Ujjal Bhuyan and K Vinod Chandran dismissed the PIL filed by lawyer Vishal Tiwari after Solicitor General Tushar Mehta objected to it. The top law officer said the petitioner reads the newspaper and rushes to the court. The bench, which was initially of the view that the notice should be issued, later dismissed it. Mehta said he was not appearing for any state at the moment but the seriousness with which states like Tamil Nadu and Madhya Pradesh are taking actions cannot be undermined. Moreover, there are proper law enforcement mechanisms in states, he added. The bench asked Tiwari as to how many PILs he has filed so far in the top court and on being told that he has moved eight to 10 such pleas so far

Pharma stocks rise as US considers exempting generics from tariffs

Among major gainers, Aurobindo Pharma led the rally, surging 4.49 per cent to Rs 1,118.9, followed by Lupin, which climbed 2.73 per cent to Rs 1,957.6

Drug regulator begins pan-Indian inspection of cough syrup makers

The regulator has sought a list of cough syrup manufacturers from all states and UTs following reports of toxic contaminants linked to child deaths in Madhya Pradesh

Mohan Yadav blames Tamil Nadu for poor cooperation in cough syrup case

After 24 child deaths linked to toxic cough syrup, Madhya Pradesh CM Mohan Yadav accuses Tamil Nadu of not cooperating in the investigation into drug safety lapses